Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro

Acta Pharmacologica Sinica

Volumn 35, Issue 3, 2014, Pages 401-409

  Wu, Li Xian ^a   Wu, Ying ^a   Chen, Rui Jia ^a   Liu, Yang ^a   Huang, Li Sen ^a   Lou, Li Guang ^b   Zheng, Zhi Hong ^a   Chen, Yuan Zhong ^a   Xu, Jian Hua ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Bcr Abl; C817; chronic myelogenous leukemia; curcumin; imatinib resistance; leukemia stem cell; mutantion

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; C 817; CRK LIKE PROTEIN; CURCUMIN; IMATINIB; PHOSPHOTRANSFERASE INHIBITOR; STAT5 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BCR-ABL1 FUSION PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; C817 CURCUMIN DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL; MTT ASSAY; MUTANT; PROTEIN PHOSPHORYLATION; STEM CELL; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; K562 CELL LINE; METABOLISM; MUTATION; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZAMIDES; CELL PROLIFERATION; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; NEOPLASTIC STEM CELLS; PHENOTYPE; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84895531593     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.180     Document Type: Article

References (33)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
2. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.
3. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487-91.
4. Perl A, Carroll M. BCR-ABL kinase is dead; long live the CML stem cell. J Clin Invest 2011; 121: 22-5.
5. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396-409.
6. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197-203.
7. Saglio G, Kim DW, Issaragrisil S, Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-9.
8. Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009; 114: 4933-8.
9. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500-5.
10. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-41.
11. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009; 27: 469-71.
12. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367: 2075-88.
13. Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006; 2: 95-102.
14. Zhang J, Adrián FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010; 463: 501-6.
15. Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 2004; 12: 3871-83.
16. Liu Y, Xu JH, Li N, Zhang NW, Xu JH. Synthesis of 3,5- dibenzylidenepiperidin-4-one analogs and their antitumor activities in vitro. Chin J Med Chem 2011; 21: 262-6.
17. Luo H, Quan H, Xie C, Xu Y, Fu L, Lou L. HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance. Leukemia 2010; 24: 1807-9.
18. Qi J, Peng H, Gu ZL, Liang ZQ, Yang CZ. Establishment of an imatinib resistant cell line K562/G01 and its characterization. Zhonghua Xue Ye Xue Za Zhi 2004; 25: 337-41.
19. Wu LX, Xu JH, Zhang KZ, Lin Q, Huang XW, Wen CX, et al. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. Leukemia 2008; 22: 1402-9.
20. van Os RP, Dethmers-Ausema B, de Haan G. In vitro assays for cobblestone area-forming cells, LTC-IC, and CFU-C. Methods Mol Biol 2008; 430: 143-57.
21. Meng A, Wang Y, Brown SA, Van ZG, Zhou D. Ionizing radiation and busulfan inhibit murine bone marrow cell hematopoietic function via apoptosis-dependent and-independent mechanisms. Exp Hematol 2003; 31: 1348-56.
22. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101: 3142-9.
23. Budak-Alpdogan T, Alpdogan O, Akoglu T. Morphological and functional characteristics of short-term and long-term bone marrow cultures in chronic myelogenous leukemia. Am J Hematol 1999; 62: 212-20.
24. Tretiakova I, Blaesius D, Maxia L, Wesselborg S, Schulze-Osthoff K, Cinatl J Jr, et al. Myrtucommulone from Myrtus communis induces apoptosis in cancer cells via the mitochondrial pathway involving caspase-9. Apoptosis 2008; 13: 119-31.
25. Tian Z, Shen J, Moseman AP, Yang Q, Yang J, Xiao P, et al. Dulxanthone A induces cell cycle arrest and apoptosis via up-regulation of p53 through mitochondrial pathway in HepG2 cells. Int J Cancer 2008; 122: 31-8.
26. Del BB, Valentini MA, Comporti M, Maellaro E. Cisplatin-induced apoptosis in melanoma cells: role of caspase-3 and caspase-7 in Apaf-1 proteolytic cleavage and in execution of the degradative phases. Ann N Y Acad Sci 2003; 1010: 200-4.
27. Troiano L, Ferraresi R, Lugli E, Nemes E, Roat E, Nasi M, et al. Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry. Nat Protoc 2007; 2: 2719-27.
28. Hassan AQ, Sharma SV, Warmuth M. Allosteric inhibition of BCR-ABL. Cell Cycle 2010; 9: 3710-4.
29. Jatiani SS, Cosenza SC, Reddy MV, Ha JH, Baker SJ, Samanta AK, et al. A non-ATP-competitive dual inhibitor of JAK2 and BCR-ABL kinases: Elucidation of a novel therapeutic spectrum based on substrate competitive inhibition. Genes Cancer 2010; 1: 331-45.
30. Weisberg E, Deng X, Choi HG, Barrett R, Adamia S, Ray A, et al. Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia 2010; 24: 1375-8.
31. Fabbro D, Manley PW, Jahnke W, Liebetanz J, Szyttenholm A, Fendrich G, et al. Inhibitors of the Abl kinase directed at either the ATP-or myristate-binding site. Biochim Biophys Acta 2010; 1804: 454-62.
32. Passegue E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 2004; 119: 431-43.
33. Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A 2003; 100: 11842-9.